Obese Patients

Source: www.moreover.com --- 9 days ago
Porter SE et al. - Morbidly Obese population had a statistically higher complication rate, longer operative times, and greater estimated intraoperative blood loss. ...

Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles Use of Endoluminal Antireflux Therapies for Obese Patients with GERD. Obes Surg. 2008 Oct 7; Authors: White B, Jeansonne LO, Cook M, Chavarriaga LF, Goldenberg EA, Davis SS, Smith CD, Khaitan L, Lin E BACKGROUND: Obese Patients with gastroesophageal reflux disease (GERD) refractory to medical therapy are a challenging patient population as obesity is a preoperative predictor of failure after antireflux surgery. We therefore sought to evaluate outcomes using one of two commercially available endoluminal therapies in this population. METHODS: Consecutive Obese Patients (body mass index (BMI) > 30) with GERD (DeMeester >14.5) undergoing either Plicator (NDO) or Stretta (Curon) were identified in our single-institution prospective database. Outcomes assessed were: (1) failure rate (absolutely no symptomatic improvement after procedure and/or need for subsequent antireflux surgery), (2) postoperative vs. preoperative symptom (heartburn, chest pain, regurgitation, dysphagia, cough, hoarseness, and asthma) scores, and (3) proton-pump inhibitor (PPI) medication use. RESULTS: Twenty-two Patients each underwent an endoluminal therapy (ten Plicator Patients and 12 Stretta Patients) with mean follow-up of 1.5 years. There were no treatment-associated complications. Mean BMI was not different between Plicator and Stretta groups (39.6 vs. 38.6, respectively, p = 0.33). The failure rate for the entire cohort was 28% (10% Plicator vs. ...

Source: www.moreover.com --- 24 days ago
MedWire News: Overweight or Obese women with breast cancer tend to have a poorer response to chemotherapy than their healthy-weight counterparts, study results show. ...

Source: www.ncbi.nlm.nih.gov --- 31 days ago
Related Articles Cardiorespiratory fitness and obstructive sleep apnea syndrome in morbidly Obese Patients. Chest. 2008 Sep;134(3):539-45 Authors: Vanhecke TE, Franklin BA, Zalesin KC, Sangal RB, Dejong AT, Agrawal V, McCullough PA BACKGROUND: Conflicting data exist regarding the effects of obstructive sleep apnea syndrome (OSAS) on cardiorespiratory fitness in morbidly Obese individuals with normal resting left ventricular function. METHODS: Ninety-two morbidly Obese subjects without any prior diagnosis of OSAS underwent cardiorespiratory fitness testing, two-dimensional echocardiography, and overnight polysomnography. Using the results of the polysomnogram, comparisons were made between subjects with (n = 42) and without (n = 50) OSAS. RESULTS: Mean body mass index (BMI) for the study population (n = 92) was 48.6 +/- 9.3 kg/m(2) (+/- SD); mean age was 45.5 +/- 9.8 years, and approximately 69% were female. Despite having a higher resting, exercise, and resting mean arterial pressures, the OSAS cohort had a maximum oxygen consumption that was lower than the cohort without OSAS (21.1 mL/kg/min vs 17.6 mL/kg/min; p < 0.001). There was no difference in BMI, age, gender, waist circumference, and neck circumference between those with and without OSAS. Differences were observed between the cohorts in systolic BP, diastolic BP, and heart rate during rest, exercise, and recovery periods. There was no difference in ejection fraction, diastolic ...

Source: www.ncbi.nlm.nih.gov --- 14 days ago
Related Articles Two-stage laparoscopic biliopancreatic diversion with duodenal switch as treatment of high-risk super-Obese Patients: analysis of complications. Surg Endosc. 2008 Sep 24; Authors: Silecchia G, Rizzello M, Casella G, Fioriti M, Soricelli E, Basso N INTRODUCTION: The aim of this study is to retrospectively analyze the incidence of complications after two-stage laparoscopic biliopancreatic diversion with duodenal switch (Lap BPD-DS) in high-risk super-Obese Patients and explore the possible predictive factors of specific complications after laparoscopic sleeve gastrectomy (SG). METHODS: High-risk Patients-body mass index (BMI) > 50 kg/m(2) with at least two major comorbidities: type 2 diabetes, obstructive sleep apnea syndrome (OSAS), hypertension-undergoing two-stage laparoscopic BPD-DS were retrospectively analysed. The SG pouch volume was 100-150 ml; in the second stage, the common channel and the alimentary loop were 100 cm and 150 cm, respectively. RESULTS: Eighty-seven Patients (50 female, 57.5%) underwent SG (two open). The mean age was 41.8 +/- 10.22 years with BMI of 55.2 +/- 6.69 kg/m(2). Four Patients had Prader-Willy syndrome. Fourteen (16.46%) Patients (6 female, 42.8%) had postoperative complications such as bleeding, fistula, pulmonary embolism, transitory acute renal failure, and abdominal abscess. One patient died at postoperative day 5 of pulmonary embolism. One patient was reoperated for hemoperitoneum ...

Source: www.ncbi.nlm.nih.gov --- 20 days ago
Related Articles Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-Obese Patients. A prospective randomized study. J Assist Reprod Genet. 2008 Sep 19; Authors: Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P PURPOSE: Embryological and clinical efficacy of gonadotropin-releasing hormone (GnRH) antagonist and agonist stimulation protocols in non-Obese women with polycystic ovarian syndrome (PCOS) were compared. METHODS: A prospective randomized study. Setting: Medical University Hospital. Patients: 70 infertile PCOS Patients; 33 in GnRH antagonist and 37 in GnRH agonist group. RESULTS: Similar mature metaphase II oocyte rate (76% vs. 76%) was observed in both protocols. Optimal pronuclear morphology zygotes dominated in both groups (64% vs. 66%). Transferred embryo quality did not differ in both protocols. No significant differences between both protocols were found in delivery rate (p = 0.481), pregnancy rate (p = 0.810), multiple pregnancy rate (p = 0.501), miscarriage rate (p = 0.154), fertilization rate (p = 0.388) and implantation rate (p = 1.000). Duration of stimulation and total follicle-stimulating hormone (FSH) dose were significantly lower in GnRH antagonist protocol (p = 0.0005). CONCLUSIONS: GnRH antagonist and agonist protocols in non-Obese PCOS Patients yield similar embryological and clinical outcomes. Shorter duration of treatme ...

Source: www.medscape.com --- 35 days ago
A study showed that obesity is associated with worse outcomes for asthma, especially hospitalizations, even after adjustment for other patient characteristics and treatment. Medscape Medical News ...

Source: www.prnewswire.com --- 38 days ago
...

Source: www.nature.com --- 22 days ago
...

Source: www.medscape.com --- 12 days ago
In a small randomized trial, exercise plus a healthy diet reduced loss of muscle mass in frail, Obese, elderly adults. Medscape Medical News ...

Source: www.moreover.com --- 33 days ago
CHEST Sep 8 2008 7:27PM GMT ...

Source: www.medicalnewstoday.com --- 33 days ago
New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in Obese Patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone1. ...

Source: www.physorg.com --- 25 days ago
Researchers at National Jewish Health have shown that glucocorticoids, the primary controller medication for asthma, are 40 percent less effective in overweight and Obese asthma Patients than in those of normal weight. The findings identify a potential mechanism involved in the resistance, which suggests therapeutic targets for future medications. The study, by Associate Professor of Medicine E. Rand Sutherland, MD, MPH and his colleagues at National Jewish Health, appears in the October 1, 2008, issue of the American Journal of Respiratory and Critical Care Medicine. ...

Source: www.medicalnewstoday.com --- 24 days ago
Researchers at National Jewish Health have shown that glucocorticoids, the primary controller medication for asthma, are 40 percent less effective in overweight and Obese asthma Patients than in those of normal weight. The findings identify a potential mechanism involved in the resistance, which suggests therapeutic targets for future medications. The study, by Associate Professor of Medicine ...

Source: www.ananova.com --- 16 days ago
...

Source: www.medicalnewstoday.com --- 19 days ago
GI Dynamics, a medical device company pioneering the development of new approaches to treating metabolic disorders, today announced that new data regarding EndoBarrier™, its novel, noninvasive device currently in clinical trials to treat obesity and type 2 diabetes, will be presented at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) 13th World Congress in Buenos Aires, Argentina. ...

Source: www.medicalnewstoday.com --- 29 days ago
Data released at the European Association for the Study of Diabetes (EASD) Annual Meeting concludes that Levemir® (insulin detemir [rDNA origin] injection) is a once-daily treatment for diabetes Patients after demonstrating a 24-hour duration of action in both type 1 and type 2 diabetes. ...

Source: www.healthcentral.com --- 40 days ago
For the same perceived severity of asthma symptoms, Obese Patients exhibit worse asthma control than their non-Obese peers, Canadian researchers have found. ...

Source: www.healthcentral.com --- 38 days ago
Novartis AG's high blood-pressure drug Tekturna was effective in hard-to-treat Patients with obesity, heart failure and diabetes, the Swiss company said on Wednesday. ...

Source: www.bignewsnetwork.com --- 24 days ago
Washington, Sept 17 : Steroids may not be as effective in Obese asthmatics as in those with normal weight, finds a new study from National Jewish Health. ...